Audentes Therapeutics, Inc., a biotechnology company committed to the development and commercialization of gene therapy products for patients with serious, rare diseases, recently announced the acquisition of Cardiogen Sciences, Inc., a biotechnology company focused on the discovery and development of adeno-associated virus(AAV) gene therapy products for rare, inherited arrhythmogenic diseases